LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Lista de Ações・Cerus Corp

Cerus Corp

Abrir

SetorSaúde

2.62 1.55

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.54

Máximo

2.71

Indicadores-chave
By Trading Economics
Rendimento	527K -1.6M
Vendas	2.1M 60M
EPS	-0.01
Margem de lucro	-2.752
Funcionários	261
EBITDA	1.9M 93K

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+73.75% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	148M 545M
Abertura anterior	1.07
Fecho anterior	2.62

Sentimento de Notícias

By Acuity

37%

63%

139 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

1.3 / 1.36 Suporte e Resistência

Cerus Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de mai. de 2026, 23:41 UTC

Ganhos

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 de mai. de 2026, 21:40 UTC

Ganhos

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 de mai. de 2026, 23:13 UTC

Ganhos

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 de mai. de 2026, 23:12 UTC

Ganhos

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 de mai. de 2026, 23:11 UTC

Ganhos

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 de mai. de 2026, 23:07 UTC

Ganhos

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 de mai. de 2026, 23:06 UTC

Ganhos

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 de mai. de 2026, 23:05 UTC

Ganhos

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 de mai. de 2026, 23:04 UTC

Ganhos

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 de mai. de 2026, 22:50 UTC

Ganhos

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 de mai. de 2026, 22:25 UTC

Conversa de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 de mai. de 2026, 22:11 UTC

Ganhos

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 de mai. de 2026, 22:05 UTC

Conversa de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 de mai. de 2026, 21:58 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:47 UTC

Conversa de Mercado

Ganhos

Costco Posts 13% Sales Growth in April -- Market Talk

6 de mai. de 2026, 21:46 UTC

Ganhos

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 de mai. de 2026, 21:40 UTC

Ganhos

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 de mai. de 2026, 21:35 UTC

Conversa de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 de mai. de 2026, 21:32 UTC

Ações em Alta

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 de mai. de 2026, 21:29 UTC

Ganhos

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparação entre Pares

Variação de preço

Cerus Corp Previsão

Preço-alvo

By TipRanks

73.75% parte superior

Previsão para 12 meses

Média 4.5 USD 73.75%

Máximo 5 USD

Mínimo 4 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Cerus Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

Comprar

Manter

Vender

Com base em 3 analistas que deram avaliações de ações para Cerus Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.3 / 1.36Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

139 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.